Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.33 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 2/20 | 0.32 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.30 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.30 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.30 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.30 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.30 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.30 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.30 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.30 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16147546 | 1.00 | SMN1; SMN2 (0.39) | SMN1; SMN2ALDH1A1MAPTPTGS1CA1 | |
| SCHEMBL16821022 | 1.00 | SMN1; SMN2 (0.39) | SMN1; SMN2ALDH1A1MAPTPTGS1CA1 | |
| Hydrochloric Acid SCHEMBL3197516 | 0.98 | SMN1; SMN2 (0.37) | SMN1; SMN2ALDH1A1MAPTPTGS1CA1 | |
| Hydrochloric Acid SCHEMBL1629944 | 0.98 | SMN1; SMN2 (0.37) | SMN1; SMN2ALDH1A1MAPTPTGS1CA1 | |
| SCHEMBL500459 | 0.82 | SMN1; SMN2 (0.42) | SMN1; SMN2ALDH1A1MAPTPTGS1CA1 | |
| SCHEMBL20879474 | 0.82 | SMN1; SMN2 (0.42) | SMN1; SMN2ALDH1A1MAPTPTGS1CA1 | |
| SCHEMBL500460 | 0.82 | SMN1; SMN2 (0.42) | SMN1; SMN2ALDH1A1MAPTPTGS1CA1 | |
| Hydrochloric Acid SCHEMBL737492 | 0.80 | SMN1; SMN2 (0.41) | SMN1; SMN2ALDH1A1MAPTPTGS1CA1 | |
| Hydrochloric Acid SCHEMBL1705950 | 0.80 | SMN1; SMN2 (0.41) | SMN1; SMN2ALDH1A1MAPTPTGS1CA1 | |
| SCHEMBL3015800 | 0.80 | SMN1; SMN2 (0.39) | SMN1; SMN2ALDH1A1MAPTPTGS1CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023023631-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. (US) | 2023-02-23 | — | — | WO | disclosed |
| US-20210206715-A1 | Benzoylglycine Derivatives and Methods of Making and Using Same | DUKE UNIVERSITY (US) | 2021-07-08 | — | — | US | disclosed |
| US-11034649-B2 | Benzoylglycine derivatives and methods of making and using same | DUKE UNIVERSITY (US) | 2021-06-15 | — | — | US | disclosed |
| US-20200085779-A1 | Compounds for the Treatment of Bovine or Swine Respiratory Disease | INTERVET INC. (US) | 2020-03-19 | — | — | US | disclosed |
| US-10550074-B2 | Benzoylglycine derivatives and methods of making and using same | DUKE UNIVERSITY (US) | 2020-02-04 | — | — | US | disclosed |
| US-20190169114-A1 | Benzoylglycine Derivatives and Methods of Making and Using Same | DUKE UNIVERSITY | 2019-06-06 | — | — | US | disclosed |
| US-20170349544-A1 | Ethynylbenzene Derivatives | DUKE UNIVERSITY | 2017-12-07 | — | — | US | disclosed |
| US-20170349544-A1 | Ethynylbenzene Derivatives | DUKE UNIVERSITY | 2017-12-07 | — | — | US | disclosed |
| US-9738604-B2 | Ethynylbenzene derivatives | DUKE UNIVERSITY (US) | 2017-08-22 | — | — | US | disclosed |
| US-9738604-B2 | Ethynylbenzene derivatives | DUKE UNIVERSITY (US) | 2017-08-22 | — | — | US | disclosed |
| WO-2012154204-A1 | HYDROXAMIC ACID DERIVATIVES AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTIONS | ACHAOGEN, INC. (US) | 2012-11-15 | — | — | WO | disclosed |
| WO-2012031298-A2 | ETHYNYLBENZENE DERIVATIVES | DUKE UNIVERSITY (US) | 2012-03-08 | — | — | WO | disclosed |
| US-7932240-B2 | Phosphadiazine HCV polymerase inhibitors IV | IDENIX PHARMACEUTICALS, INC. (US) | 2011-04-26 | — | — | US | disclosed |
| US-20100190766-A1 | ANTIBACTERIAL AGENTS | ACHAOGEN, INC. (US) | 2010-07-29 | — | — | US | disclosed |
| US-20100190766-A1 | ANTIBACTERIAL AGENTS | ACHAOGEN, INC. (US) | 2010-07-29 | — | — | US | disclosed |
| US-20100029609-A1 | BIARYL SULFONAMIDE DERIVATIVES | NOVARTIS AG (CH) | 2010-02-04 | — | — | US | disclosed |
| EP-2081888-A1 | N-BIARYL (HETERO) ARYLSULPHONAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF DISEASES MEDIATED BY LYMPHOCYTES INTERACTIONS | Novartis AG (CH) | 2009-07-29 | — | — | EP | disclosed |
| US-20090081158-A1 | PHOSPHADIAZINE HCV POLYMERASE INHIBITORS IV | IDENIX PHARMACEUTICALS, INC. (US) | 2009-03-26 | — | — | US | disclosed |
| WO-2008154642-A2 | ANTIBACTERIAL AGENTS | ACHAOGEN, INC. (US) | 2008-12-18 | — | — | WO | disclosed |
| WO-2008028937-A1 | N-BIARYL (HETERO) ARYLSULPHONAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF DISEASES MEDIATED BY LYMPHOCYTES INTERACTIONS | NOVARTIS AG (CH) | 2008-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210206715-A1 | Benzoylglycine Derivatives and Methods of Making and Using Same | B3GAT3, GLO1, GLMN | SMN1; SMN2 3138/4885ALDH1A1 1477/4885MAPT 4583/4885 |
| US-20090081158-A1 | PHOSPHADIAZINE HCV POLYMERASE INHIBITORS IV | POLI, ITPA, POLR2H | SMN1; SMN2 4370/4885ALDH1A1 1722/4885MAPT 4232/4885 |
| US-11034649-B2 | Benzoylglycine derivatives and methods of making and using same | B3GAT3, GLO1, GLMN | SMN1; SMN2 3138/4885ALDH1A1 1477/4885MAPT 4583/4885 |
| US-20100190766-A1 | ANTIBACTERIAL AGENTS | MRPL21, SI, ABCB11 | SMN1; SMN2 2202/4885ALDH1A1 687/4885MAPT 4643/4885 |
| US-20190169114-A1 | Benzoylglycine Derivatives and Methods of Making and Using Same | B3GAT3, GLO1, GLMN | SMN1; SMN2 3138/4885ALDH1A1 1477/4885MAPT 4583/4885 |
| US-10550074-B2 | Benzoylglycine derivatives and methods of making and using same | B3GAT3, GLO1, GLMN | SMN1; SMN2 3138/4885ALDH1A1 1477/4885MAPT 4583/4885 |
| US-20100029609-A1 | BIARYL SULFONAMIDE DERIVATIVES | UGT2B7, CYP3A7, STS | SMN1; SMN2 1493/4885ALDH1A1 1114/4885MAPT 3961/4885 |
| US-20170349544-A1 | Ethynylbenzene Derivatives | Q6ZSR9, EPX, ZYX | SMN1; SMN2 4714/4885ALDH1A1 1651/4885MAPT 4533/4885 |
| US-20200085779-A1 | Compounds for the Treatment of Bovine or Swine Respiratory Disease | PIGS, BTD, PPARD | SMN1; SMN2 2973/4885ALDH1A1 1567/4885MAPT 2161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.